Matej Zrimsek

Dr. Matej Zrimsek


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MZMatej Zrimsek
Matej Zrimsek
Jakob GubensekJakob Gubensek
Jakob Gubensek
APAndreja Marn Pernat
Andreja Marn Pernat
Background: Therapeutic plasma exchange (TPE) removes coagulation factors and leads to depletion coagulopathy. The aim of the study was to compare hemostasis between TPE procedures without coagulation factor replacement (electrolyte group), the partial replacement of fibrinogen with fibrinogen concentrates (fibrinogen group) and partial coagulation factors replacement with fresh frozen plasma (partial FFP group). Methods: A total of 73 TPE procedures in patients with fibrinogen levels 1–2 g/L were divided into three study groups depending on clinically estimated bleeding risk. Standard coagulation and ROTEM® tests were performed before and after TPE. Results: Fibrinogen levels before TPE (p = 0.88) and after TPE (p = 0.33) were comparable between the fibrinogen and partial FFP groups. INR and ROTEM® parameters reflected moderately worse hemostasis after TPE with fibrinogen-only replacement compared to partial FFP replacement, which could result in increased bleeding risk. In the electrolyte group, most laboratory tests confirmed the most deranged hemostasis after TPE, as compared to fibrinogen or partial FFP replacement. A mild allergic reaction to FFP infusion was noted during one TPE. No clinically significant bleeding occurred in any of the study groups. Conclusions: Fibrinogen concentrate supplementation and partial FFP replacement can both maintain fibrinogen levels > 1 g/L after TPE, but modest differences in classical coagulation tests and bedside ROTEM® tests favor FFP replacement (NCT03801135).

1 January 2021 in Clinical Nephrology
Verified
Journal Article
Closed access
MZMatej Zrimsek
Matej Zrimsek
APAndreja Marn Pernat
Andreja Marn Pernat
Aims: In therapeutic plasma exchange (TPE), large amounts of plasma with all components, including antibodies, albumin, coagulation factors and inhibitors, are removed and usually replaced with replacement fluid without coagulation factors. Hemostatic parameters should be closely monitored in patients at risk of bleeding or with large volume exchanges with a short recovery interval. In this prospective study, we compared standard coagulation parameters and the rotational thromboelastometry (ROTEM) point-of-care test to identify hemostatically severely compromised patients treated with TPE. Materials and methods: 22 patients without recent or planned invasive procedures received 63 TPE treatments with regional citrate anticoagulation. One plasma volume was exchanged with replacement fluid containing albumin and electrolytes. Standard coagulation tests, fibrinogen concentration, and rotational thromboelastometry (ROTEM, including EXTEM test, INTEM test, and FIBTEM test) were performed before and after each TPE treatment. Results: Fibrinogen concentration decreased significantly and international normalized ratio increased slightly after TPE. Activated partial thromboplastin time, EXTEM, INTEM, and FIBTEM clotting times as well as clot formation times were prolonged, and maximum clot firmness decreased after TPE procedures. No serious adverse events occurred during TPE treatment. Conclusion: Our study showed that ROTEM parameters changed significantly after TPE performed with replacement fluid without coagulation factors. Among all parameters, FIBTEM clotting time showed the highest percentual change after TPE. According to this data, the ROTEM point-of-care test may have a potential to guide TPE therapy, particularly in patients at high risk for bleeding.

9 September 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
MZMatej Zrimsek
Matej Zrimsek
Jakob GubensekJakob Gubensek
Jakob Gubensek
Many therapeutic apheresis procedures that remove plasma or plasma components also lower coagulation factor levels, which can increase patients’ bleeding risk. In this narrative review, we sum up data on clotting factor removal and the development of dilutional coagulopathy mostly associated with therapeutic plasma exchange (TPE) treatment and consider available tests for coagulation assessment. It is common in clinical practice to check fibrinogen levels regularly during repetitive TPE treatments and use it as a marker of hemostasis because of its long half-life and central role in hemostasis. We discuss the background of current clinical practice regarding fibrinogen thresholds discuss different threshold levels and data on the associated risk of bleeding. We stress the importance of additional bleeding risk assessment when patients are exposed to concomitant invasive procedures. We also describe the possibilities for fibrinogen replacement during TPE treatments with either fresh frozen plasma or fibrinogen concentrate and the associated effect on factor XIII levels. Finally, we briefly discuss alternative apheresis procedures regarding their fibrinogen-sparing potential.